S&P 500

6.071,17

0,53%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Pluri Inc (PLUR)
Pluri Inc (PLUR) Notícias

PLUR

Pluri (PLUR)

Pluri Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:PLUR

1 2 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
29/01/2025	10:53	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PLUR	Pluri Inc
23/01/2025	09:15	GlobeNewswire Inc.	Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition	NASDAQ:PLUR	Pluri Inc
19/12/2024	10:00	GlobeNewswire Inc.	Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease	NASDAQ:PLUR	Pluri Inc
09/12/2024	11:00	GlobeNewswire Inc.	Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025	NASDAQ:PLUR	Pluri Inc
25/11/2024	10:30	GlobeNewswire Inc.	Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns	NASDAQ:PLUR	Pluri Inc
28/10/2024	08:00	GlobeNewswire Inc.	Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority	NASDAQ:PLUR	Pluri Inc
30/09/2024	17:00	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:PLUR	Pluri Inc
20/09/2024	17:00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PLUR	Pluri Inc
18/09/2024	17:00	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:PLUR	Pluri Inc
18/07/2024	03:30	GlobeNewswire Inc.	Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates	NASDAQ:PLUR	Pluri Inc
08/07/2024	08:00	GlobeNewswire Inc.	Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply	NASDAQ:PLUR	Pluri Inc
18/06/2024	07:30	GlobeNewswire Inc.	Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges	NASDAQ:PLUR	Pluri Inc
06/06/2024	07:45	GlobeNewswire Inc.	U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract	NASDAQ:PLUR	Pluri Inc
20/05/2024	08:00	GlobeNewswire Inc.	Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale	NASDAQ:PLUR	Pluri Inc
09/05/2024	17:13	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:PLUR	Pluri Inc
09/05/2024	17:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PLUR	Pluri Inc
02/05/2024	08:00	GlobeNewswire Inc.	Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment	NASDAQ:PLUR	Pluri Inc
08/04/2024	08:00	GlobeNewswire Inc.	Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method	NASDAQ:PLUR	Pluri Inc
28/03/2024	08:15	GlobeNewswire Inc.	Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences	NASDAQ:PLUR	Pluri Inc
27/03/2024	08:00	GlobeNewswire Inc.	Pluri Inc. Announces 1-for-8 Reverse Share Split	NASDAQ:PLUR	Pluri Inc
21/03/2024	08:00	GlobeNewswire Inc.	Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report	NASDAQ:PLUR	Pluri Inc
19/03/2024	05:00	GlobeNewswire Inc.	Engage with Pluri's Talent: Exciting Conference Appearances Ahead	NASDAQ:PLUR	Pluri Inc
14/03/2024	08:00	GlobeNewswire Inc.	Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing	NASDAQ:PLUR	Pluri Inc
11/03/2024	08:00	GlobeNewswire Inc.	Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation	NASDAQ:PLUR	Pluri Inc
06/03/2024	09:00	GlobeNewswire Inc.	Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board	NASDAQ:PLUR	Pluri Inc
28/02/2024	09:00	GlobeNewswire Inc.	Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals	NASDAQ:PLUR	Pluri Inc
14/02/2024	19:43	Edgar (US Regulatory)	Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:PLUR	Pluri Inc
13/02/2024	18:34	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:PLUR	Pluri Inc
23/01/2024	04:00	GlobeNewswire Inc.	Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis	NASDAQ:PLUR	Pluri Inc
21/12/2023	09:00	GlobeNewswire Inc.	Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction	NASDAQ:PLUR	Pluri Inc